Search results
Results from the WOW.Com Content Network
The Parkinson's Disease Foundation is a leading national presence in the United States in Parkinson's disease research, education and public advocacy. PDF works on behalf of people who live with Parkinson's disease by funding promising clinical research to find treatments and cures for Parkinson's. [30]
In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief ...
Ali R. Rezai (born 1965) [1] is an Iranian-born American neurosurgeon and neuroscientist. [2] [3] His work and research has focused on neuromodulation treatments for patients with neurological and mental health conditions, [4] including neuromodulation techniques such as deep brain stimulation (DBS) through brain chip implants to treat Parkinson's disease tremors, obsessive–compulsive ...
The researchers inserted the device into two patients with Parkinson's disease who had traditional DBS but continued to experience dyskinesia after adjustment by a neurologist. Later on, they compared the results of the adaptive stimulation system with traditional stimulation set manually on two patients, and found that the adaptive approach ...
However, with this treatment, the number of substantia nigra neurons decrease so it becomes less efficient. [2] These treatments try to reduce the symptoms of the patient focusing on increasing the production of dopamine but they do not cure the disease. The new treatments for PD are in clinical trials and most of them are centered on gene therapy.
Moussa B. H. Youdim (born, February 28, 1940) is a world famous Israeli neuroscientist specializing in neurochemistry and neuropharmacology. He is the discoverer of both monoamine oxidase (MAO) B inhibitors l-deprenyl and rasagiline as anti-Parkinson drugs which possess neuroprotective activities.
In January 2021 the FDA approved the first clinical trial for an investigational stem cell therapy to restore lost brain cells in people with advanced Parkinson's disease. [ 40 ] Healthy adult brains contain neural stem cells , which divide to maintain general stem-cell numbers, or become progenitor cells .
Pardoprunox (code name SLV-308) is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued. [1] [2] [3] It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well. [1]